Protection Systems Reduce Stroke and Mortality in Carotid Artery Stenting

So far, the main controlled randomized studies have almost exclusively been aimed at comparing the efficacy and safety of carotid artery stenting vs. endarterectomy. Almost all of them have left at operator discretion the choice of the devices to be used during the procedure, which is why there is few direct information to help us make a decision on the cerebral protection system to use, stent material or design, the need for intraprocedural neurophysiological monitoring, and the type of antiplatelet therapy.

Protection Systems Reduce Stroke and Mortality in Carotid Artery Stenting

The aim of this study was to analyze the association between intraprocedural and periprocedural variables and in-hospital stroke and death rates after carotid artery stenting.

 

This trial enrolled a total of 13,086 patients who underwent carotid artery stenting procedures for asymptomatic (63.9%) or symptomatic disease.


Read also: “Estudio SENTINEL: Protección cerebral durante el TAVI”.


The following variables were analyzed: stent design, stent material, neurophysiological monitoring, antiplatelet medication, and use of a cerebral protection system. The primary endpoint was the rate of in-hospital stroke or death.

 

The primary outcome occurred in 2.4% of the population (1.7% in asymptomatic and 3.7% in symptomatic patients).

 

A multivariable analysis showed an independent association between the use of a cerebral protection system and lower in-hospital rates of stroke or death (relative risk [RR]: 0.65; 95% confidence interval [CI]: 0.50 to 0.85), disabling stroke or death (RR: 0.60; 95% CI: 0.43 to 0.84), and stroke (RR: 0.57; 95% CI: 0.43 to 0.77). In the analysis of death rates, no association was found between this event and the use of a cerebral protection system (RR: 0.78; 95% CI: 0.46 to 1.35).


Read also: La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos”.


There was no significant association between stent design, stent material, neurophysiological monitoring, or antiplatelet medication and events such as stroke or death.

 

Conclusion

The use of a cerebral protection system was the only technical variable in carotid artery stenting associated with lower rates of in-hospital stroke and death.

 

Editorial

Retrospective and indirect evidence, plus rationality in the use of cerebral protection systems during carotid artery stenting, resulted in the non-existence of randomized studies testing the usefulness of these devices. We simply adopt them, almost without asking questions. This work with over 13,000 patients is the largest study supporting the idea of always using cerebral protection systems.

 

As regards stent design, this work showed a trend of lower event rates with closed-cell stents, while featuring a wide confidence interval. There is evidence in favor and against both designs. Furthermore, no study has considered parameters such as plaque morphology or vessel anatomy. The most likely scenario is for different patients to benefit from different designs (e.g., open-cell stents for tortuous arteries or closed-cell stents for soft and unstable plaque).

 

Stent material (nitinol or stainless steel) was not associated with events.

 

Antiplatelet medication was not associated with events either, which is both surprising and suspicious. This could be easily explained by the fact that only 2% of patients did not receive antiplatelet medication. Conclusion: Physicians will always indicate dual-antiplatelet therapy.

 

Neurophysiological monitoring showed a trend towards higher rates of stroke and death, but the clear problem here is that the indication was at operator discretion. Neurophysiological monitoring was very probably indicated for those who were suspected of being high-risk patients.

 

Original title: The Use of Embolic Protection Devices Is Associated with a Lower Stroke and Death Rate After Carotid Stenting.

Reference: Christoph Knappich et al. J Am Coll Cardiol Intv 2017;10:1257-65.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...